Jill M. Van Dalfsen

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

Steven M. Rowe, Sonya L. Heltshe, Tanja Gonska et al. · American Journal of Respiratory and Critical Care Medicine · 2014 · 491 citations · Full text

Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis

Jane L. Burns, Jill M. Van Dalfsen, Ribhi M. Shawar et al. · The Journal of Infectious Diseases · 1999 · 287 citations · Full text

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

David P. Nichols, Sarah J. Morgan, M. Skalland et al. · Journal of Clinical Investigation · 2023 · 181 citations · Full text

Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare

Ribhi M. Shawar, D J Humble, Jill M. Van Dalfsen et al. · Antimicrobial Agents and Chemotherapy · 1997 · 52 citations · Full text

How much do <i>Pseudomonas</i> biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?

Donald R. VanDevanter, Jill M. Van Dalfsen · Pediatric Pulmonology · 2005 · 50 citations